NuCana plc: NuCana Reports Preliminary Data from Phase II Study of Single-Agent Acelarin (NUC-1031) in Patients with Platinum-Resistant Ovarian Cancer
2020-03-10
Confirmed Complete Response and Two Partial Responses Achieved in Heavily Pre-treated Population Patients had Median of Five Prior Lines of Therapy EDINBURGH, United Kingdom, March 10, 2020 (GLOBE ...
适应症
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。